Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Merck Ord Shs MKGAF

Alternate Symbol(s): MKKGY

Healthcare

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical... see more

Add To Watchlist

Recent & Breaking News (OTCPK:MKGAF)

Merck Announces Recipients of the Grant for Growth Innovation 2017

PR Newswire Europe Non Regulatory September 18, 2017

Merck KGaA, Darmstadt, Germany Announces Recipients of the Grant for Growth Innovation 2017

PR Newswire September 18, 2017

Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance

PR Newswire September 11, 2017

Merck ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research

PR Newswire Europe Non Regulatory September 10, 2017

Merck KGaA, Darmstadt, Germany, ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research

PR Newswire September 10, 2017

Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment

PR Newswire Europe Non Regulatory September 5, 2017

European Commission Grants Approval for Mavenclad (Cladribine Tablets)

PR Newswire Europe Non Regulatory August 25, 2017

EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

PR Newswire July 21, 2017

Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne

PR Newswire Europe Non Regulatory June 29, 2017

Data Provide Additional Insight Into the Mode of Action of MAVENCLAD™ (Cladribine Tablets) in Patients With Relapsing MS

PR Newswire Europe Non Regulatory June 26, 2017

Merck to Present Data on MAVENCLAD™ (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

PR Newswire Europe Non Regulatory June 24, 2017

Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis

PR Newswire Europe Non Regulatory June 23, 2017

Merck Honors World MS Day by Launching Care Partner Survey with IACO

PR Newswire Europe Non Regulatory May 31, 2017

‘It’s not you. It’s your thyroid.’ Campaign Launched to Raise Awareness of Symptoms

PR Newswire Europe Non Regulatory May 22, 2017

100 Healthy Years - Are Kids Prepared?

Canada NewsWire May 19, 2017

Shaping Cancer Care Today and Tomorrow: Merck, KGaA, Darmstadt, Germany, to Present New Data from Rapidly Evolving Pipeline at ASCO 2017

PR Newswire May 17, 2017

Shaping Cancer Care Today and Tomorrow: Merck to Present New Data from Rapidly Evolving Pipeline at ASCO 2017

PR Newswire Europe Non Regulatory May 17, 2017

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017

PR Newswire May 17, 2017

Merck's Glucophage® SR Receives Label Extension for Patients at High Risk of Type 2 Diabetes in the UK

PR Newswire Europe Non Regulatory May 17, 2017

European Commission Grants Approval for Merck's New Pergoveris® Pen for Fertility Treatment

PR Newswire Europe Non Regulatory May 10, 2017